MX2019014876A - Compuestos heteroaromaticos como inhibidores de vanina. - Google Patents
Compuestos heteroaromaticos como inhibidores de vanina.Info
- Publication number
- MX2019014876A MX2019014876A MX2019014876A MX2019014876A MX2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A
- Authority
- MX
- Mexico
- Prior art keywords
- heteroaromatic compounds
- compounds
- vanin
- inhibitors
- vanin inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención abarca los compuestos de la Fórmula (I) (ver Fórmula) en donde los grupos A y B se definen en la presente, que son adecuados para el tratamiento de enfermedades relacionadas con vanina, y los procesos para fabricar estos compuestos, las preparaciones farmacéuticas que contienen estos compuestos y sus métodos de uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518106P | 2017-06-12 | 2017-06-12 | |
| PCT/EP2018/065140 WO2018228934A1 (en) | 2017-06-12 | 2018-06-08 | Heteroaromatic compounds as vanin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019014876A true MX2019014876A (es) | 2020-02-13 |
| MX394645B MX394645B (es) | 2025-03-21 |
Family
ID=62631060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014876A MX394645B (es) | 2017-06-12 | 2018-06-08 | Compuestos heteroaromáticos como inhibidores de vanina. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10364255B2 (es) |
| EP (1) | EP3638680B1 (es) |
| JP (1) | JP6880243B2 (es) |
| KR (1) | KR102607934B1 (es) |
| CN (1) | CN110770242B (es) |
| AR (1) | AR112086A1 (es) |
| AU (1) | AU2018285131B2 (es) |
| CA (1) | CA3066946A1 (es) |
| CL (1) | CL2019003515A1 (es) |
| CO (1) | CO2019013823A2 (es) |
| DK (1) | DK3638680T3 (es) |
| EA (1) | EA039223B1 (es) |
| ES (1) | ES2927021T3 (es) |
| HU (1) | HUE060597T2 (es) |
| IL (1) | IL271104B (es) |
| MA (1) | MA49374A (es) |
| MX (1) | MX394645B (es) |
| PE (1) | PE20200340A1 (es) |
| PH (1) | PH12019502693A1 (es) |
| PL (1) | PL3638680T3 (es) |
| TW (1) | TWI855993B (es) |
| WO (1) | WO2018228934A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| AU2018285131B2 (en) * | 2017-06-12 | 2021-11-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
| PE20211089A1 (es) | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
| AU2019326933B2 (en) * | 2018-08-28 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
| WO2020104494A1 (en) | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| US12358910B2 (en) | 2018-12-03 | 2025-07-15 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
| EA202191476A1 (ru) | 2018-12-03 | 2021-10-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Гетероароматические соединения в качестве ингибиторов ванина |
| AU2019392524B2 (en) | 2018-12-03 | 2025-05-08 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as vanin inhibitors |
| CN114269755A (zh) | 2019-09-12 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物 |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| EP4696293A1 (en) | 2023-04-10 | 2026-02-18 | Umov SPA | Rehabilitation and monitoring system |
| WO2025261536A1 (zh) * | 2024-06-21 | 2025-12-26 | 长春金赛药业有限责任公司 | 一种整联蛋白配体关键中间体及其制备方法 |
| CN118892548A (zh) * | 2024-08-12 | 2024-11-05 | 中国人民解放军陆军特色医学中心 | Vanin-1抑制剂在制备治疗急性肾损伤继发急性肺损伤的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2540868A1 (en) | 2003-10-09 | 2005-04-21 | Abbott Laboratories | Pyrrolidinyl urea derivatives as angiogenesis inhibitors |
| US10308615B2 (en) * | 2015-05-29 | 2019-06-04 | Pfizer Inc. | Heterocyclic compounds as inhibitors of Vanin-1 enzyme |
| WO2018011681A1 (en) * | 2016-07-14 | 2018-01-18 | Pfizer Inc. | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
| AU2018285131B2 (en) * | 2017-06-12 | 2021-11-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
-
2018
- 2018-06-08 AU AU2018285131A patent/AU2018285131B2/en active Active
- 2018-06-08 MX MX2019014876A patent/MX394645B/es unknown
- 2018-06-08 US US16/003,252 patent/US10364255B2/en active Active
- 2018-06-08 CA CA3066946A patent/CA3066946A1/en active Pending
- 2018-06-08 JP JP2019566724A patent/JP6880243B2/ja active Active
- 2018-06-08 EA EA202090014A patent/EA039223B1/ru unknown
- 2018-06-08 CN CN201880039562.3A patent/CN110770242B/zh active Active
- 2018-06-08 PE PE2019002531A patent/PE20200340A1/es unknown
- 2018-06-08 DK DK18731766.4T patent/DK3638680T3/da active
- 2018-06-08 KR KR1020197038628A patent/KR102607934B1/ko active Active
- 2018-06-08 EP EP18731766.4A patent/EP3638680B1/en active Active
- 2018-06-08 WO PCT/EP2018/065140 patent/WO2018228934A1/en not_active Ceased
- 2018-06-08 ES ES18731766T patent/ES2927021T3/es active Active
- 2018-06-08 HU HUE18731766A patent/HUE060597T2/hu unknown
- 2018-06-08 MA MA049374A patent/MA49374A/fr unknown
- 2018-06-08 PL PL18731766.4T patent/PL3638680T3/pl unknown
- 2018-06-11 TW TW107119946A patent/TWI855993B/zh active
- 2018-06-11 AR ARP180101573A patent/AR112086A1/es unknown
-
2019
- 2019-05-13 US US16/410,037 patent/US20190263828A1/en not_active Abandoned
- 2019-11-28 PH PH12019502693A patent/PH12019502693A1/en unknown
- 2019-12-02 IL IL271104A patent/IL271104B/en unknown
- 2019-12-02 CL CL2019003515A patent/CL2019003515A1/es unknown
- 2019-12-09 CO CONC2019/0013823A patent/CO2019013823A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110770242A (zh) | 2020-02-07 |
| KR20200013718A (ko) | 2020-02-07 |
| EA039223B1 (ru) | 2021-12-20 |
| EP3638680B1 (en) | 2022-08-10 |
| PH12019502693A1 (en) | 2020-07-13 |
| MA49374A (fr) | 2021-04-21 |
| AU2018285131B2 (en) | 2021-11-11 |
| AR112086A1 (es) | 2019-09-18 |
| US10364255B2 (en) | 2019-07-30 |
| IL271104B (en) | 2022-03-01 |
| CO2019013823A2 (es) | 2020-01-17 |
| MX394645B (es) | 2025-03-21 |
| PE20200340A1 (es) | 2020-02-14 |
| DK3638680T3 (da) | 2022-09-05 |
| TWI855993B (zh) | 2024-09-21 |
| CL2019003515A1 (es) | 2020-06-19 |
| TW201920196A (zh) | 2019-06-01 |
| WO2018228934A1 (en) | 2018-12-20 |
| JP6880243B2 (ja) | 2021-06-02 |
| HUE060597T2 (hu) | 2023-04-28 |
| JP2020522517A (ja) | 2020-07-30 |
| CA3066946A1 (en) | 2018-12-20 |
| IL271104A (en) | 2020-01-30 |
| EP3638680A1 (en) | 2020-04-22 |
| US20180354968A1 (en) | 2018-12-13 |
| KR102607934B1 (ko) | 2023-12-01 |
| EA202090014A1 (ru) | 2020-05-12 |
| AU2018285131A1 (en) | 2019-10-31 |
| PL3638680T3 (pl) | 2022-12-19 |
| US20190263828A1 (en) | 2019-08-29 |
| BR112019021703A2 (pt) | 2020-05-12 |
| ES2927021T3 (es) | 2022-11-02 |
| CN110770242B (zh) | 2022-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019014876A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| MY197440A (en) | Heteroamatic compounds as btk inhibitors | |
| SA521422152B1 (ar) | Vanin مركبات عطرية غير متجانسة كمثبطات | |
| PH12021550269A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
| PH12020500252A1 (en) | Compounds as modulators of ror gamma | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MY195427A (en) | Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease | |
| SA515360007B1 (ar) | مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk) | |
| PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
| CA2983453A1 (en) | Naphthyridine compounds as jak kinase inhibitors | |
| MX378732B (es) | Formas solidas novedosas | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202090414A1 (ru) | Соединения и их применение | |
| MX2021006490A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| PH12016502568A1 (en) | Novel heterocyclic compound | |
| MX380776B (es) | Derivados de pirazolilaminobenzimidazol como inhibidores de jak. | |
| MX385475B (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa |